WallStSmart

Hinge Health, Inc. (HNGE)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 9145% more annual revenue ($66.57B vs $720.06M). HNGE leads profitability with a 15.1% profit margin vs 4.8%. HNGE trades at a lower P/E of 11.3x. HNGE earns a higher WallStSmart Score of 52/100 (C-).

HNGE

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 6.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -2.69

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HNGE.

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$144.85

$62.01 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HNGE3 strengths · Avg: 10.0/10
P/E RatioValuation
11.3x10/10

Attractively priced relative to earnings

Revenue GrowthGrowth
53.0%10/10

Revenue surging 53.0% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

HNGE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
22.1x2/10

Trading at 22.1x book value

Return on EquityProfitability
-197.2%2/10

ROE of -197.2% — below average capital efficiency

EPS GrowthGrowth
-68.4%2/10

Earnings declined 68.4%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HNGE

The strongest argument for HNGE centers on P/E Ratio, Revenue Growth, Debt/Equity. Profitability is solid with margins at 15.1% and operating margin at 19.0%. Revenue growth of 53.0% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : HNGE

The primary concerns for HNGE are Piotroski F-Score, Price/Book, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

HNGE profiles as a growth stock while MRK is a value play — different risk/reward profiles.

HNGE is growing revenue faster at 53.0% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HNGE scores higher overall (52/100 vs 36/100), backed by strong 15.1% margins and 53.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hinge Health, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Hinge Health, Inc. develops health care software for joint and muscle health. The company is headquartered in San Francisco, California.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?